Financial Daily from THE HINDU group of publications
Friday, Mar 03, 2006


News
Features
Stocks
Shipping
Archives
Google

Group Sites

Corporate - Mergers & Acquisitions


Marksans Pharma acquires Australian co

Our Bureau

Mumbai , March 2

Marksans Pharma Ltd has entered into an agreement with Nova Pharmaceuticals Ltd, Australia to acquire the majority stake in Nova Pharmaceuticals Australasia PTY Ltd.

The move would help Marksans Pharma leverage its manufacturing capabilities and strengthen its global foothold, the company told the BSE.

This is one of the first major investments by the company in the international pharma market. Marksans has a manufacturing facility with regulatory approvals from Australia and the Nova acquisition will provide a synergy, the company said. The Australian pharmaceutical market is growing as the demand for medicine continues to rise.

More Stories on : Mergers & Acquisitions | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
Chinese co opens liaison office


Hyundai cuts car prices
Sujana Metal, Universal offer equity to SASF
Sical to raise $125 m thru convertible bonds, GDRs
Matrix Labs EGM clears GDR offer
`Certified Internal Auditor' course
Roche gets product patent on Hepatitis C
Meridian Ind to merge with Precot Mills
HLL sells TEIL to Woodbriar Group
Marksans Pharma acquires Australian co
Bannari Amman to set up bio-diesel plant
Svendgaard plans facility in Himachal
Haldia Petro uncertain of Budget impact on finances
Hetero Drugs plans to tap capital market next fiscal
CTMTC to sell 5 m spindles this year
Bajaj 2, 3-wheeler sales up 30% in Feb
Tata Motors sales up 22%
Honda sales up 24 pc in Feb
Ford India posts 47% growth
MICO deputy MD joins US co



The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line